NYSE:EBS - Emergent Biosolutions Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Emergent Biosolutions Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $59.91 -1.53 (-2.49 %) (As of 02/26/2020 04:01 AM ET) Add Compare Today's Range$59.40Now: $59.91▼$63.5050-Day Range$53.54MA: $58.88▼$65.9452-Week Range$39.11Now: $59.91▼$71.19Volume439,814 shsAverage Volume327,106 shsMarket Capitalization$3.09 billionP/E Ratio58.17Dividend YieldN/ABeta1.53 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNYSE:EBS Previous Symbol CUSIP29089Q10 CIK1367644 Webhttp://www.emergentbiosolutions.com/ Phone240-631-3200Debt Debt-to-Equity Ratio0.73 Current Ratio3.17 Quick Ratio2.14Price-To-Earnings Trailing P/E Ratio58.17 Forward P/E Ratio16.88 P/E Growth0.93 Sales & Book Value Annual Sales$1.11 billion Price / Sales2.80 Cash Flow$4.68 per share Price / Cash Flow12.80 Book Value$21.08 per share Price / Book2.84Profitability EPS (Most Recent Fiscal Year)$2.91 Net Income$54.50 million Net Margins4.94% Return on Equity14.19% Return on Assets6.37%Miscellaneous Employees1,705 Outstanding Shares51,624,000Market Cap$3.09 billion Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive EBS News and Ratings via Email Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. EBS Rates by TradingView Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions What is Emergent Biosolutions' stock symbol? Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS." How will Emergent Biosolutions' stock buyback program work? Emergent Biosolutions declared that its board has authorized a stock repurchase plan on Friday, March 23rd 2018, which permits the company to repurchase $50,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued. How were Emergent Biosolutions' earnings last quarter? Emergent Biosolutions Inc (NYSE:EBS) released its quarterly earnings results on Thursday, February, 20th. The biopharmaceutical company reported $1.57 EPS for the quarter, missing the Zacks' consensus estimate of $1.67 by $0.10. The biopharmaceutical company had revenue of $360.40 million for the quarter, compared to the consensus estimate of $357.18 million. Emergent Biosolutions had a return on equity of 14.19% and a net margin of 4.94%. Emergent Biosolutions's quarterly revenue was up 33.3% compared to the same quarter last year. During the same period last year, the firm earned $0.75 earnings per share. View Emergent Biosolutions' Earnings History. When is Emergent Biosolutions' next earnings date? Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Emergent Biosolutions. What guidance has Emergent Biosolutions issued on next quarter's earnings? Emergent Biosolutions issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.175-1.275 billion, compared to the consensus revenue estimate of $1.23 billion. What price target have analysts set for EBS? 6 analysts have issued 12 month price objectives for Emergent Biosolutions' shares. Their forecasts range from $65.00 to $75.00. On average, they expect Emergent Biosolutions' stock price to reach $70.83 in the next year. This suggests a possible upside of 18.2% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions. What is the consensus analysts' recommendation for Emergent Biosolutions? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions. What are Wall Street analysts saying about Emergent Biosolutions stock? Here are some recent quotes from research analysts about Emergent Biosolutions stock: 1. Cantor Fitzgerald analysts commented, ". Post 1Q19, we reiterate our Overweight rating and our 12- month price target of $75. EBS continues to be the leader in the biodefense field, and the acquisition of Adapt and PaxVax leverage the company’s historical expertise, while further diversifying revenue away from BioThrax. We continue to believe the company’s business is a lot more durable than the Street is giving it credit for, and we expect Emergent to extend a number of its current contracts beyond current estimates, as well as bring some significant pipeline product to market over time. Emergent does not have the risk of commercial insurance reimbursement or payer pricing pressures on the majority of its portfolio." (5/2/2019) 2. According to Zacks Investment Research, "Emergent BioSolutions' recent acquisitions of PaxVax and Adapt Pharma have expanded the company’s presence in the public health threats market. Its anthrax vaccine, NuThrax’s regulatory application is under review, with a decision expected in the first half of 2019. We are positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the cost structure. Notably, the company derives majority of its revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is a headwind. Moreover, Emergent depends on certain single-source suppliers for key materials and services, which are necessary for manufacturing BioThrax. This, in turn, raises a concern. Shares of the company have underperformed the industry so far this year. Estimates have narrowed ahead of Q1 earnings. Emergent has a mixed record of earnings surprises in the recent quarters." (4/8/2019) Has Emergent Biosolutions been receiving favorable news coverage? Media headlines about EBS stock have trended very negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Emergent Biosolutions earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Emergent Biosolutions. Are investors shorting Emergent Biosolutions? Emergent Biosolutions saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,610,000 shares, an increase of 6.5% from the January 15th total of 2,450,000 shares. Based on an average trading volume of 307,300 shares, the days-to-cover ratio is currently 8.5 days. Currently, 6.1% of the company's stock are short sold. View Emergent Biosolutions' Current Options Chain. Who are some of Emergent Biosolutions' key competitors? Some companies that are related to Emergent Biosolutions include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Emergent Biosolutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include Mercadolibre (MELI), Broadcom (AVGO), Global Payments (GPN), Netflix (NFLX), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), NXP Semiconductors (NXPI), CalAmp (CAMP) and Gentherm (THRM). Who are Emergent Biosolutions' key executives? Emergent Biosolutions' management team includes the folowing people: Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 61)Mr. Robert G. Kramer Sr., CEO, Pres & Director (Age 62)Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 55)Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 46)Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 48) Who are Emergent Biosolutions' major shareholders? Emergent Biosolutions' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (4.00%), Earnest Partners LLC (3.94%), Goldman Sachs Group Inc. (2.18%), Rice Hall James & Associates LLC (2.13%), Renaissance Technologies LLC (1.48%) and Jennison Associates LLC (1.24%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions. Which institutional investors are selling Emergent Biosolutions stock? EBS stock was sold by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Renaissance Technologies LLC, Tygh Capital Management Inc., Marshall Wace LLP, Rice Hall James & Associates LLC, Mutual of America Capital Management LLC, UBS Group AG and Bank of America Corp DE. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, Kathryn C Zoon, Sue Bailey and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions. Which institutional investors are buying Emergent Biosolutions stock? EBS stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Earnest Partners LLC, Eaton Vance Management, State Street Corp, Loomis Sayles & Co. L P, Goldman Sachs Group Inc., FMR LLC and Prudential Financial Inc.. View Insider Buying and Selling for Emergent Biosolutions. How do I buy shares of Emergent Biosolutions? Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Emergent Biosolutions' stock price today? One share of EBS stock can currently be purchased for approximately $59.91. How big of a company is Emergent Biosolutions? Emergent Biosolutions has a market capitalization of $3.09 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $54.50 million in net income (profit) each year or $2.91 on an earnings per share basis. Emergent Biosolutions employs 1,705 workers across the globe.View Additional Information About Emergent Biosolutions. What is Emergent Biosolutions' official website? The official website for Emergent Biosolutions is http://www.emergentbiosolutions.com/. How can I contact Emergent Biosolutions? Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected] MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 378 (Vote Outperform)Underperform Votes: 330 (Vote Underperform)Total Votes: 708MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/26/2020 by MarketBeat.com StaffFeatured Article: What member countries make up the G-20?
